Rechallenge of docetaxel combined with epirubicin given on a weekly schedule in advanced castration-resistant prostate cancer patients previously exposed to docetaxel and abiraterone acetate: a single-institution experience.
about
Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate.Is there still a place for docetaxel rechallenge in prostate cancer?Costunolide enhances doxorubicin-induced apoptosis in prostate cancer cells via activated mitogen-activated protein kinases and generation of reactive oxygen species.RNA interference-mediated depletion of TRPM8 enhances the efficacy of epirubicin chemotherapy in prostate cancer LNCaP and PC3 cells.
P2860
Rechallenge of docetaxel combined with epirubicin given on a weekly schedule in advanced castration-resistant prostate cancer patients previously exposed to docetaxel and abiraterone acetate: a single-institution experience.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Rechallenge of docetaxel combi ...... single-institution experience.
@en
Rechallenge of docetaxel combi ...... single-institution experience.
@nl
type
label
Rechallenge of docetaxel combi ...... single-institution experience.
@en
Rechallenge of docetaxel combi ...... single-institution experience.
@nl
prefLabel
Rechallenge of docetaxel combi ...... single-institution experience.
@en
Rechallenge of docetaxel combi ...... single-institution experience.
@nl
P2093
P2860
P50
P1433
P1476
Rechallenge of docetaxel combi ...... single-institution experience.
@en
P2093
A I Fiaschi
G Barbanti
G De Rubertis
R Petrioli
Salvatora T Miano
P2860
P2888
P356
10.1007/S12032-015-0485-2
P577
2015-01-31T00:00:00Z